New Frontiers, Landmark Trials, and Evolving Treatment Paradigms for MS and PD-A Year 2010 Best Practice Update for the Neurology Specialist
C. Warren Olanow, MD, FRCPC

The Evidence for First-Line Therapy in MS with Immune-Modulating Agents: From Mechanisms to Therapy-Landmark Trials, Long-Term Safety Data, and Clinical Experience
Howard L. Zwibel, MD

The Emergence of Immunosuppressive Agents for MS: Safety, Efficacy, and Cautionary Notes-Patient Monitoring, Risk for Infection, and Mechanisms of Action
Douglas R. Jeffrey, MD, PhD

Case Studies, Question and Answer Session
Faculty Panel